Recall

FDA clocks record number of recalls

The regulator has already issued more recalls in the first half of 2014 than it has over the past nine years.

India establishes inspection guidelines

The new rules are expected to do away with the haphazard nature of facility inspections.

Sun recalls cancer drug

It's the generics maker's second recall of 2014.

Takeda walks away from Omontys

The drugmaker is pulling its US marketing application for the anemia drug.

Alexion recalls some Soliris batches

The US-only recall amounts to less than 1% of the company's inventory.

J&J posts third-quarter progress

J&J posts third-quarter progress

By

The company beat consensus estimates, with particular sales strengths from its pharmaceuticals division.

Boehringer shutters problematic Ohio plant

1,100 workers will lose their jobs at a plant with a history of around 40 recalls.

Business Briefs: GSK, Astellas, Vertex and Orexigen

GSK and Astellas kick off the race for a new anemia treatment; Orexigen's CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment.

Business briefs: Élan, Teva

A buyout offer upsets Elan's post-Tysabri plans, Takeda and Affymax recall Omontys.

J&J OTC sales slipped 3% in 2012 worldwide

By

CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year's numbers.

J&J says no shakeup at McNeil Consumer Healthcare unit

By

J&J is pushing back hard against a Wall Street Journal article suggesting that a pair of retirements and a promotion are part of a corporate shakeup of its recall-plagued McNeil Consumer Healthcare division.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.